Novaremed AG, a newly incorporated Swiss clinical-stage biopharmaceutical company raised CHF 4.44 million from private investors. The funds will be used to prepare for a Phase 2b clinical study of its lead compound, NRD.E1, a novel, first-in-class, small molecule for patients suffering from diabetic neuropathic pain (DNP).
VISCHER AG assisted Novaremed in the legal transfer from Israel to Basel and the financing round. The team is led by our Partners Matthias Staehelin (Corporate) and Nadia Tarolli (Tax) with Vincent Reardon (Senior Associate), Sebastian Flückiger (Associate) both Corporate and Martin Dubach (Senior Associate) Tax.